Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in ...

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...

An expected delay in a key step in CK Hutchison's planned sale of its Panama ports to a U.S. group, a deal blasted by Chinese ...

Several global studies, including the widely cited STEP 1 trial, have shown that discontinuing weight-loss medication often ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported ...

JACKSON, WY / ACCESS Newswire / April 1, 2025 / Labor Smart, Inc. (OTC PINK:LTNC), through its newest subsidiary Elevate ...

Affordable and alternative versions of popular weigh loss drugs, like Ozempic and Wegovy, may no longer be available.

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

An estimated 15 million Americans are currently taking semaglutide weight loss drugs, which are proven to impact alcohol ...

Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and ...

Genetics or hormonal changes can pose challenges for losing weight, as you may know firsthand. Like many others struggling to ...

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, ...